Maxalt-MLT

See also: Generic Maxalt

Maxalt-MLT is a brand name of rizatriptan, approved by the FDA in the following formulation(s):

MAXALT-MLT (rizatriptan benzoate - tablet, orally disintegrating; oral)

• 
  Manufacturer: MERCK
  
  Approval date: June 29, 1998
  
  Strength(s): EQ 10MG BASE ^[RLD], EQ 5MG BASE
  

Has a generic version of Maxalt-MLT been approved?

No. There is currently no therapeutically equivalent version of Maxalt-MLT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Maxalt-MLT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Triazole containing indole derivatives
  Patent 5,298,520
  Issued: March 29, 1994
  Inventor(s): Baker; Raymond & Matassa; Victor G. & Street; Leslie J.
  Assignee(s): Merck Sharp & Dohme Limited
  A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
  
  Patent expiration dates:
  
  
  • June 29, 2012
    
    ✓ 
    Patent use: TREATMENT OF ACUTE MIGRAINE ATTACKS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 29, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of identifying freeze-dried dosage forms
  Patent 5,457,895
  Issued: October 17, 1995
  Inventor(s): Thompson; Andrew R. & Yarwood; Richard J. & Kearney; Patrick
  Assignee(s): R. P. Scherer Corporation
  The invention permits the application of an identifying mark onto a freeze-dried tablet without the need for application of pressure or for printing directly on the tablet. The invention comprises the preparation of a freeze-dried unit that is embossed with an identifying mark such as a manufacturer's logo, medicinal component strength, or other information relating to the unit. The desired identifying mark is first embossed onto the base of a container such as a blister pocket. Liquid suspension is then filled into the container and freeze-dried therein. The resulting freeze-dried unit in the container is thereby embossed with substantial copy of the identifying mark that was embossed on the base of the container. The embossed identifying mark on the base of the container remains thereon as well, providing at reduced manufacturing cost the added ability to learn the identifying mark on the enclosed freeze-dried unit without opening the blister pack.
  
  Patent expiration dates:
  
  
  • October 1, 2013
    
    ✓ 
    Drug product
  
  
  
  • April 1, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Imidazole, triazole and tetrazole derivatives
  Patent 5,602,162
  Issued: February 11, 1997
  Inventor(s): Baker; Raymond & Matassa; Victor G. & Street; Leslie J.
  Assignee(s): Merck, Sharp & Dohme Ltd.
  A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
  
  Patent expiration dates:
  
  
  • February 11, 2014
    
    ✓ 
    Patent use: TREATMENT OF ACUTE MIGRAINE ATTACKS
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • August 11, 2014
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2014 - NEW PATIENT POPULATION
  
  
  • June 15, 2015 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Maxalt-MLT Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Maxalt-MLT Consumer Information (Cerner Multum)
• Maxalt-MLT Advanced Consumer Information (Micromedex)
• Rizatriptan Consumer Information (Wolters Kluwer)
• Rizatriptan Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Rizatriptan Consumer Information (Cerner Multum)
• Rizatriptan Advanced Consumer Information (Micromedex)
• Rizatriptan Benzoate AHFS DI Monographs (ASHP)